Additionally, ezrinThr-567 correlated with the overall survival time of patients with NSCLC, and both ezrin and ezrinThr-567 overexpression were correlated with shorter survival time in patients with early stage NSCLC. Here, EZR is linked to non-small cell lung carcinoma.